What are the differential diagnoses for albinism?

Differential Diagnosis of Albinism

When evaluating a patient with suspected albinism, you must systematically distinguish between non-syndromic oculocutaneous albinism (OCA) and life-threatening syndromic forms that require urgent recognition and treatment, particularly Chediak-Higashi syndrome (CHS), Griscelli syndrome type 2 (GS2), and Hermansky-Pudlak syndrome type 2 (HPS2).

Critical Syndromic Forms with Immunodeficiency

The most important differential diagnoses are syndromic albinism variants that carry significant morbidity and mortality risk 1:

Chediak-Higashi Syndrome (CHS)

• Key distinguishing features: Partial oculocutaneous albinism + recurrent pyogenic bacterial infections + progressive neurological symptoms (cognitive impairment, photophobia, nystagmus, cerebellar/spinal/peripheral neuropathies) 1
• Pathognomonic finding: Giant azurophilic lysosomal granules in all granulated cells on peripheral blood smear 1
• Life-threatening complication: Virtually all patients develop hemophagocytic lymphohistiocytosis (HLH) "accelerated phase" with high fever, hepatosplenomegaly, pancytopenia, and neurological deterioration—fatal without aggressive treatment 1
• Additional features: Bleeding diathesis, gingivitis, oral ulcerations, periodontal disease 1
• First diagnostic test: Peripheral blood smear examination 1

Griscelli Syndrome Type 2 (GS2)

• Key distinguishing features: Oculocutaneous hypopigmentation + silvery grey hair + recurrent pyogenic infections + neurological abnormalities (seizures, ataxia, oculomotor abnormalities) 1
• Diagnostic hair finding: Large melanin clumps in hair shaft 1
• Critical pitfall: Many patients have normal screening immune function tests even with active infections 1
• Life-threatening complication: Accelerated phase of HLH, usually in infancy/childhood, occasionally delayed to second decade 1
• Hepatosplenomegaly: Frequent at presentation 1

Note on GS subtypes: GS1 (neurological symptoms, minimal infections), GS2 (infections + neurological symptoms), GS3 (hypopigmentation only, no infections/neurological signs) 1

Hermansky-Pudlak Syndrome Type 2 (HPS2)

• Key distinguishing features: Oculocutaneous albinism + severe thrombocytopenia/thrombasthenia + neutropenia + recurrent infections 1
• Distinguishing from other HPS types: Only HPS2 (among 9 HPS subtypes) presents with immunodeficiency 1, 2
• Additional feature: Idiopathic pulmonary fibrosis (less common in HPS2 than other HPS types) 1

MAPBP-Interacting Protein (MAPBPIP) Deficiency

• Unique distinguishing feature: Albinism with short stature 2
• Additional features: Chronic neutropenia, immunodeficiency 2

Non-Syndromic Forms (Lower Mortality Risk)

Oculocutaneous Albinism (OCA) Types 1-8

• Clinical spectrum: Ranges from complete melanin absence (OCA1A) to milder forms with some pigment accumulation (OCA1B, OCA2, OCA3, OCA4) 3
• Ocular findings: Congenital nystagmus, iris hypopigmentation/translucency, foveal hypoplasia, reduced visual acuity (20/60 to 20/400), refractive errors, photophobia, optic nerve misrouting 3, 4
• Most common subtypes: OCA1 in Europeans, OCA2 in Sub-Saharan Africans 5
• Key point: Normal lifespan, development, intelligence, and fertility; no systemic complications beyond increased skin cancer risk 3

Ocular Albinism (OA)

• Inheritance: X-linked recessive 6
• Key distinguishing feature: Reduced retinal and iris pigmentation WITHOUT skin involvement 6
• Ocular manifestations: Nystagmus, macular hypoplasia, substantial visual acuity loss 6

Other Differential Diagnoses

Clinical Phenocopies Requiring Consideration 7

When additional features are present beyond typical albinism:

• Progressive preschool-age myopia: Consider Knobloch syndrome, Stickler syndrome
• Hearing loss: Consider Waardenburg syndrome type II, Donnai-Barrow syndrome 7, 3
• Seizures: Consider specific syndromic forms
• Abnormal chest imaging: Consider Jeune syndrome
• Easy bruising: Consider HPS variants

Other Hypopigmentation Disorders 8

• Piebaldism
• Waardenburg syndrome
• Vitiligo
• Pityriasis alba
• Tuberous sclerosis
• Halo naevus
• Postinflammatory depigmentation

Diagnostic Algorithm

Step 1: Assess for life-threatening syndromic forms

• Obtain peripheral blood smear immediately if infections present (look for giant granules in CHS) 1
• Evaluate for fever, hepatosplenomegaly, lymphadenopathy (HLH accelerated phase) 1
• Check complete blood count (neutropenia in HPS2/MAPBPIP; pancytopenia in HLH)

Step 2: Identify distinguishing clinical features

• Neurological symptoms + infections → CHS or GS2
• Bleeding tendency + neutropenia → HPS2
• Short stature → MAPBPIP deficiency
• Hearing loss or progressive myopia → Consider phenocopies 7
• Skin/hair only (no ocular) → Non-albinism hypopigmentation disorder

Step 3: Perform targeted testing

• Hair shaft examination for melanin clumps (GS2) 1
• Platelet function studies (HPS)
• NK cell and T-cell cytotoxicity (impaired in syndromic forms) 2
• Molecular genetic testing via next-generation sequencing for definitive diagnosis 4

Critical Clinical Pitfalls

1. Do not rely on normal immune screening tests to rule out GS2—many patients have normal results despite active infections 1

2. Recognize that HLH accelerated phase is fatal without treatment in CHS and GS2—requires immediate chemotherapy and immunosuppression 1

3. Understand that HSCT does not correct oculocutaneous albinism or neurological manifestations in CHS, only prevents HLH 1

4. Molecular diagnosis is essential due to significant clinical overlap between subtypes—phenotypic classification alone is insufficient 6, 4

5. Early-onset or progressive myopia, hearing loss, or other systemic features should prompt investigation beyond simple OCA 7